作为类风湿性关节炎的辅助策略的内关节甲基酸载微海绵:局部治疗具有系统影响的局部治疗
Patrizia Nadia Hanieh1, Noemi Fiaschini1, Anna Scotto d'Abusco2
1Nanofaber S.r.l., Via Anguillarese 301, 00123 Rome, Italy.
ACS biomaterials science & engineering
|February 24, 2026
概括
关节内甲状腺素微球 (MTX-MSP) 通过增强关节药物保留和减少全身毒性,提供持续性类风湿性关节炎 (RA) 治疗. 这种局部治疗在体外和体外表现出显著的抗炎作用.
科学领域:
- 生物材料科学 生物材料科学
- 类风湿病学 类风湿病学
- 药物输送系统 药物输送系统
背景情况:
- 类风湿性关节炎 (RA) 涉及慢性关节炎症和破坏.
- 目前的甲索特雷克萨 (MTX) 治疗在关节向和全身毒性方面存在局限性.
- 关节内 (IA) 药物输送提供了局部治疗潜力.
研究的目的:
- 开发和评估一个内关节甲状腺载微海绵 (MTX-MSP) 配方,用于增强RA治疗.
- 评估MTX-MSP的持续释放,生物相容性和抗炎疗效.
- 在临床前RA模型中研究IA MTX-MSP的治疗潜力.
主要方法:
- 使用 Hyaluronic 酸交叉链接合成的 MTX-MSP.
- 药物释放和载体稳定性在病态的人类突液 (HSF) 中进行评估.
- 在 RA 纤维细胞样同胞细胞的体外研究以及在原诱导性关节炎小鼠模型中的体内疗效.
主要成果:
- 在HSF中,MTX-MSP在14天内表现出持续的药物释放,爆发释放最小.
- 风病学分析证实了可注射性和与突液的良好相互作用.
- 在体外,MTX-MSP与自由MTX相比显著降低了促炎性细胞因子 (IL-6,TNF-α,IL-1β).
- 在体内,IA MTX-MSP改善了关节组织学,并建议系统性免疫调节.
结论:
- IA MTX-MSP提供了长时间的药物释放和强大的抗炎活性,用于RA.
- 这种配方增强局部药物保留,最大限度地减少全身暴露和毒性.
- MTX-MSP是一种有前途的局部药物输送策略,用于治疗类风湿性关节炎.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
602
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
602
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
646
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
646


